Interplay between human STING genotype and bacterial NADase activity regulates inter-individual disease variability.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
06 07 2023
Historique:
received: 16 08 2022
accepted: 28 06 2023
medline: 10 7 2023
pubmed: 7 7 2023
entrez: 6 7 2023
Statut: epublish

Résumé

Variability in disease severity caused by a microbial pathogen is impacted by each infection representing a unique combination of host and pathogen genomes. Here, we show that the outcome of invasive Streptococcus pyogenes infection is regulated by an interplay between human STING genotype and bacterial NADase activity. S. pyogenes-derived c-di-AMP diffuses via streptolysin O pores into macrophages where it activates STING and the ensuing type I IFN response. However, the enzymatic activity of the NADase variants expressed by invasive strains suppresses STING-mediated type I IFN production. Analysis of patients with necrotizing S. pyogenes soft tissue infection indicates that a STING genotype associated with reduced c-di-AMP-binding capacity combined with high bacterial NADase activity promotes a 'perfect storm' manifested in poor outcome, whereas proficient and uninhibited STING-mediated type I IFN production correlates with protection against host-detrimental inflammation. These results reveal an immune-regulating function for bacterial NADase and provide insight regarding the host-pathogen genotype interplay underlying invasive infection and interindividual disease variability.

Identifiants

pubmed: 37414832
doi: 10.1038/s41467-023-39771-0
pii: 10.1038/s41467-023-39771-0
pmc: PMC10326033
doi:

Substances chimiques

Bacterial Proteins 0
NAD+ Nucleosidase EC 3.2.2.5
STING1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4008

Informations de copyright

© 2023. The Author(s).

Références

Infect Immun. 1980 Feb;27(2):444-8
pubmed: 6991416
Infect Immun. 2005 Oct;73(10):6562-6
pubmed: 16177331
J Infect Dis. 2000 Oct;182(4):1117-28
pubmed: 10979908
FEMS Microbiol Lett. 2000 Oct 15;191(2):235-41
pubmed: 11024269
mBio. 2017 Sep 12;8(5):
pubmed: 28900022
PLoS Pathog. 2005 Dec;1(4):e35
pubmed: 16333395
J Clin Invest. 2015 Sep;125(9):3545-59
pubmed: 26258415
Intensive Care Med. 2019 Sep;45(9):1241-1251
pubmed: 31440795
Nat Immunol. 2016 Sep 20;17(10):1142-9
pubmed: 27648547
Sci Rep. 2015 Jul 15;5:12057
pubmed: 26174161
Ann Eugen. 1951 Mar;15(4):323-54
pubmed: 24540312
PLoS Pathog. 2011 May;7(5):e1001345
pubmed: 21625574
Rev Infect Dis. 1988 Jul-Aug;10 Suppl 2:S274-6
pubmed: 3055197
Mol Microbiol. 2004 Jun;52(6):1665-76
pubmed: 15186416
J Biol Chem. 2010 Feb 19;285(8):5683-94
pubmed: 20018886
J Clin Microbiol. 2002 Jul;40(7):2642-4
pubmed: 12089296
Front Immunol. 2020 Feb 21;11:238
pubmed: 32153571
Nature. 2020 Oct;586(7829):429-433
pubmed: 32877915
Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):E1768-76
pubmed: 24733896
J Bacteriol. 2010 Jul;192(14):3735-46
pubmed: 20494994
J Infect Dis. 2005 Sep 1;192(5):771-82
pubmed: 16088826
PLoS One. 2012;7(11):e49837
pubmed: 23185452
Infect Immun. 2019 May 21;87(6):
pubmed: 30936159
J Biol Chem. 2006 Mar 24;281(12):8216-23
pubmed: 16431917
Mol Microbiol. 2002 Apr;44(1):257-69
pubmed: 11967084
Cell Rep. 2013 May 30;3(5):1355-61
pubmed: 23707065
Clin Infect Dis. 2021 Jan 27;72(2):293-300
pubmed: 31923305
Nucleic Acids Res. 2021 Jan 8;49(D1):D884-D891
pubmed: 33137190
Genes Immun. 2019 Jan;20(1):82-89
pubmed: 29728611
PLoS One. 2013 Oct 21;8(10):e77846
pubmed: 24204993
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
EMBO Rep. 2010 May;11(5):400-5
pubmed: 20339385
Hum Genet. 2020 Jun;139(6-7):681-694
pubmed: 32462426
Cell. 2001 Jan 12;104(1):143-52
pubmed: 11163247
Cell Host Microbe. 2016 Mar 9;19(3):375-87
pubmed: 26962946
PLoS Pathog. 2016 Mar 03;12(3):e1005468
pubmed: 26938870
Lancet Infect Dis. 2005 Nov;5(11):685-94
pubmed: 16253886
PLoS Pathog. 2018 Mar 26;14(3):e1006969
pubmed: 29579113
Genes Immun. 2011 Jun;12(4):263-9
pubmed: 21248775

Auteurs

Elin Movert (E)

Department of Biology, Lund University, Sölvegatan 35, 223 62, Lund, Sweden.

Jaume Salgado Bolarin (JS)

Department of Biology, Lund University, Sölvegatan 35, 223 62, Lund, Sweden.

Christine Valfridsson (C)

Department of Biology, Lund University, Sölvegatan 35, 223 62, Lund, Sweden.

Jorge Velarde (J)

Division of Infectious Diseases, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, USA.

Steinar Skrede (S)

Department of Medicine, Haukeland University Hospital, Bergen, Norway.
Department of Clinical Science, University of Bergen, Bergen, Norway.

Michael Nekludov (M)

Department of Anaesthesia, Surgical Services and Intensive Care, Karolinska University Hospital, Stockholm, Sweden.

Ole Hyldegaard (O)

Department of Anaesthesia, Head and Orthopedic Center, Rigshospitalet, Copenhagen, Denmark.
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Per Arnell (P)

Department of Anaesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden.

Mattias Svensson (M)

Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Anna Norrby-Teglund (A)

Centre for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Kyu Hong Cho (KH)

Department of Biology, Indiana State University, Terre Haute, USA.

Eran Elhaik (E)

Department of Biology, Lund University, Sölvegatan 35, 223 62, Lund, Sweden.

Michael R Wessels (MR)

Division of Infectious Diseases, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, USA.

Lars Råberg (L)

Department of Biology, Lund University, Sölvegatan 35, 223 62, Lund, Sweden.

Fredric Carlsson (F)

Department of Biology, Lund University, Sölvegatan 35, 223 62, Lund, Sweden. fredric.carlsson@biol.lu.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH